SonoVascular, a medical device company specializing in the development of the SonoThrombectomy™ System, has entered into an exclusive clinical supply agreement with Lantheus Holdings, Inc. 

The collaboration aims to utilize Lantheus' microbubbles in conjunction with SonoVascular's innovative SonoThrombectomy System to treat deep vein thrombosis (DVT) and pulmonary embolism (PE).

The SonoThrombectomy System represents a breakthrough in venous thromboembolism (VTE) treatment, integrating ultrasound, microbubbles, low-dose thrombolytic drug, and mechanical retrieval or aspiration via an intravascular catheter system. By harnessing microbubble-mediated cavitation, the system addresses the deficiencies of existing interventional devices, offering a safer and more effective solution for patients with DVT and PE.

Under the agreement, Lantheus will provide its microbubbles and activation devices for ongoing pre-clinical and upcoming clinical studies. SonoVascular will lead the execution of clinical trials and future regulatory submissions, as well as oversee commercialization efforts. Following the completion of a first-in-human (FIH) study, SonoVascular has the option to enter into a long-term exclusive commercial supply agreement with Lantheus.

Etienne Montagut, Chief Business Officer of Lantheus, expressed excitement about the partnership stating, "We are excited to partner with SonoVascular to extend our microbubble franchise into a novel treatment for VTE. Our collaboration with SonoVascular leverages both companies' strengths to help change the paradigm in the treatment of venous disease - a large and growing clinical condition."

Daniel Estay, Founder and Chief Executive Officer of SonoVascular, emphasized the significance of the partnership with Lantheus in advancing their mission to provide innovative solutions for DVT and PE treatment. "SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development," said Estay.

The SonoThrombectomy System has undergone successful evaluation in in vitro and in vivo preclinical studies. With plans to initiate FIH studies in 2024, SonoVascular and Lantheus are poised to evaluate the safety and feasibility of the system for DVT and PE treatment, paving the way for future key studies in the United States for both indications.